goralatide has been researched along with Leukemia L 1210 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Konings, AW; Wierenga, PK | 2 |
2 other study(ies) available for goralatide and Leukemia L 1210
| Article | Year |
|---|---|
Seraspenide (AcSDKP) mediated protection of hematopoietic stem cells in a hyperthermic purging protocol.
Topics: Amino Acid Sequence; Animals; Bone Marrow Purging; Cell Division; Colony-Forming Units Assay; Hematopoietic Stem Cells; Hot Temperature; Leukemia L1210; Mice; Mice, Inbred CBA; Molecular Sequence Data; Oligopeptides; S Phase | 1994 |
Goralatide (AcSDKP) selectively protects murine hematopoietic progenitors and stem cells against hyperthermic damage.
Topics: Amino Acid Sequence; Animals; Bone Marrow Purging; Cell Cycle; Cell Division; Cell Survival; Cells, Cultured; Female; Fluorouracil; Growth Inhibitors; Hematopoietic Stem Cells; Hyperthermia, Induced; Leukemia L1210; Mice; Mice, Inbred CBA; Molecular Sequence Data; Neoplastic Stem Cells; Oligopeptides; Tumor Cells, Cultured | 1996 |